Join to View Full Profile
Johns Hopkins Hospital600 N Wolfe StreetBaltimore, MD 21287
Phone+1 410-955-5000
Dr. Kanakry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013- Johns Hopkins UniversityResidency, Internal Medicine, 2007 - 2010
Duke University School of MedicineClass of 2007
Certifications & Licensure
MD State Medical License 2010 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Clinical Trials
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Start of enrollment: 2021 Sep 23
Roles: Principal Investigator, Contact
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies Start of enrollment: 2022 May 23
Roles: Contact, Principal Investigator
- Optimizing PTCy Dose and Timing Start of enrollment: 2019 Jul 09
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation.Rohtesh S Mehta, Hannah Choe, Jennifer Saultz, Zimu Gong, Prashant Sharma
American Journal of Hematology. 2025-03-12 - Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gra...Cindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, Rizwan Romee, Navneet S Majhail
Transplantation and Cellular Therapy. 2025-03-01 - Genetic testing to identify hereditary predispositions to haematological malignancy is critical prior to allogenic haematopoietic cell transplant.Amra Kajdic, Natalie T Deuitch, Erica Bresciani, Joie Davis, Kathleen Craft
British Journal of Haematology. 2025-03-01
Press Mentions
Drug Regimen Enough to Control Immune Disease After Some Bone Marrow TransplantsOctober 8th, 2014- How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow TransplantsNovember 13th, 2013
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
